Are you scheduled for or planning to have a biopsy done at UNC Health? For this trial, we are looking for people who are 18 years or older who are suspected or diagnosed with Stage IV/metastatic cancer, including: • Lung: Non-small cell lung cancer (NSCLC), • Head and Neck: Squamous Cell Carcinoma (HSNCC), excluding nasopharyngeal and salivary gland cancer; • Kidney: Clear Cell Renal Cell Carcinoma (ccRCC); • Bladder: Urothelial Carcinoma (UC); Skin: Cutaneous Melanoma, excluding Uveal Melanoma.

Have you been diagnosed with triple negative breast cancer and have residual disease after receiving preoperative therapy and surgery?

Do you have metastatic renal cell carcinoma? If so, you may be able to take part in a research study collecting information about how your therapy is affecting your quality of life.

Do you have stage III colon cancer? Have you already completed surgery? If so, you may qualify for a study that uses a blood test called ctDNA to determine your treatment and to monitor for recurrence.

Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.

Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.

Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Help shape the future of lupus! Do you want to provide a game-changing contribution to lupus-centered research? Help us make clinical research more efficient and effective. If you have lupus, you can participate by providing samples we can study, such as blood, urine, saliva, and/or stool, to help doctors combat lupus head-on. Compensation provided.